From October 19 and 20-21, 2022, the consortia meetings of REsolution and RESOLUTE took place in Berlin. The event, hosted by Bayer, gathered 60 international participants. The REsolution and RESOLUTE consortia are public-private research partnerships supported by the Innovative Health Initiative (IHI), the European Union and EFPIA, coordinated by CeMM and Pfizer, and with partners from academia and the pharmaceutical industry. The RESOLUTE project aims at intensifying worldwide research on solute carrier (SLC) transporters and to establish them as a novel target class for medical research, while the REsolution project aims at understanding how genetic variants in humans affect the function of cellular SLCs.

On October 19, 2022, REsolution scientists worked in four groups to define the strategies for single-variant studies and SLC-family wide analyses. On October 20 and 21, 2022, the focus was on RESOLUTE scientific progress. In the last years, RESOLUTE has developed many biological resources and data sets focused on SLCs. In the last year of the project, it is the perfect time to use the project’s data sets in high-impact scientific articles. To that end, scientists presented the most promising subprojects, and they got key feedback to perform the final experiments. Another highlight of the event was the three keynote lectures presented by Melissa Miller (Pfizer), Michael Brands (Bayer) and Avner Schlessinger (Icahn School of Medicine at Mount Sinai). The final session was the RESOLUTE training activity: speed dating for participants to discuss a variety of topics one-to-one.

Thank you to all participants for joining the event and engaging in meaningful exchanges with all partners, and to special thanks to the speakers for their excellent presentations!